SAB Biotherapeutics (SABS) just unveiled an update.
The Company has announced the appointment of Mr. Conley through a press release on May 30, 2024. This information, while provided to the public, is not intended for legal liability under the Securities Exchange Act of 1934, nor is it to be included in any future securities filings unless explicitly stated.
For a thorough assessment of SABS stock, go to TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
